Author’s response to the editorial commentary, “TL1A and DR3 in IBD: from mucosal immunopathology to a new era of targeted therapy”
Clicks: 1
ID: 318934
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #81 of 85 articles by views in inflammatory bowel diseases
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract is not available for this article.
Login to Search Abstract
| Reference Key |
openalex_W7166027840
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Suresh de Silva |
| Journal | inflammatory bowel diseases |
| Year | 2026 |
| DOI |
10.1093/ibd/izag136
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.